AI assistant
Arcus Biosciences, Inc. — Director's Dealing 2025
Oct 9, 2025
31966_dirs_2025-10-08_2e9d54e6-fea1-428b-8aae-39c4bed9bee3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Arcus Biosciences, Inc. (RCUS)
CIK: 0001724521
Period of Report: 2025-10-06
Reporting Person: Jarrett Jennifer (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-10-06 | Common Stock | M | 12500 | $1.2276 | Acquired | 226732 | Direct |
| 2025-10-06 | Common Stock | S | 12500 | $14.5441 | Disposed | 214232 | Direct |
| 2025-10-08 | Common Stock | M | 37792 | $1.2276 | Acquired | 252024 | Direct |
| 2025-10-08 | Common Stock | S | 37792 | $15.0458 | Disposed | 214232 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-10-06 | Stock Option (Right to Buy) | $1.2276 | M | 12500 | Disposed | 2027-03-14 | Common Stock (12500) | Direct |
| 2025-10-08 | Stock Option (Right to Buy) | $1.2276 | M | 37792 | Disposed | 2027-03-14 | Common Stock (37792) | Direct |
Footnotes
F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: Includes 863 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5: The option is fully vested and currently exercisable.